Alector, INC 10-K annual reports

Alector, a clinical-stage biotechnology company, reported a net loss of $142.9 million in 2025, alongside pipeline advancements for nivisnebart and preclinical programs, and a significant workforce reduction.

Alector's annual report highlights clinical advancements in neurodegenerative disease treatments, strategic collaborations, and financial adjustments for sustained growth.

Alector Inc.'s 10-K filing outlines the company's capital stock structure, including common and preferred stock, and details various provisions that could have anti-takeover effects.